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Abstract
Background: Liposomal-based gadolinium (Gd) nanoparticles have elicited significant interest for use as blood pool and
molecular magnetic resonance imaging (MRI) contrast agents. Previous generations of liposomal MR agents contained
gadolinium-chelates either within the interior of liposomes (core-encapsulated gadolinium liposomes) or presented on the
surface of liposomes (surface-conjugated gadolinium liposomes). We hypothesized that a liposomal agent that contained
both core-encapsulated gadolinium and surface-conjugated gadolinium, defined herein as dual-mode gadolinium (Dual-Gd)
liposomes, would result in a significant improvement in nanoparticle-based T1 relaxivity over the previous generations of
liposomal agents. In this study, we have developed and tested, both in vitro and in vivo, such a dual-mode liposomal-based
gadolinium contrast agent.
Methodology/Principal Findings: Three types of liposomal agents were fabricated: core-encapsulated, surface-conjugated
and dual-mode gadolinium liposomes. In vitro physico-chemical characterizations of the agents were performed to
determine particle size and elemental composition. Gadolinium-based and nanoparticle-based T1 relaxivities of various
agents were determined in bovine plasma. Subsequently, the agents were tested in vivo for contrast-enhanced magnetic
resonance angiography (CE-MRA) studies. Characterization of the agents demonstrated the highest gadolinium atoms per
nanoparticle for Dual-Gd liposomes. In vitro, surface-conjugated gadolinium liposomes demonstrated the highest T1
relaxivity on a gadolinium-basis. However, Dual-Gd liposomes demonstrated the highest T1 relaxivity on a nanoparticle-
basis. In vivo, Dual-Gd liposomes resulted in the highest signal-to-noise ratio (SNR) and contrast-to-noise ratio in CE-MRA
studies.
Conclusions/Significance: The dual-mode gadolinium liposomal contrast agent demonstrated higher particle-based T1
relaxivity, both in vitro and in vivo, compared to either the core-encapsulated or the surface-conjugated liposomal agent.
The dual-mode gadolinium liposomes could enable reduced particle dose for use in CE-MRA and increased contrast
sensitivity for use in molecular imaging.
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Introduction
T1-based MR contrast agents, exemplified by conventional low
molecular-weight Gd-chelates have enabled contrast enhanced
MRI for various applications such as tumor detection and
characterization as well as vascular imaging [1–3]. For both of
these applications, the T1 relaxivity of the agent can affect
detection and anatomic demarcation of normal anatomy as well as
pathology by reducing the T1 relaxation rate of tissue and
generating positive contrast in T1-weighted images. In contrast-
enhanced MR angiography (CE-MRA), conventional low molec-
ular weight contrast agents extravasate into the extravascular-
extracellular compartment (EEC) rather quickly, leaving a short
window for imaging the vessel lumen. This can lead to blurring of
the resulting images and low vessel conspicuity, particularly for
smaller vessels. The problem is further exacerbated if the bolus is
not appropriately timed, which can severely limit imaging of both
large and small vessels. One approach to circumventing the need
for accurate bolus timing involves the use of agents with longer
intravascular half-life [4,5]. Slower extravasation reduces blurring
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ratio between vascular structures and surrounding tissues. In
addition, an agent with high T1 relaxivity can also improve
imaging of small features by increasing the amount of signal
generated within the vascular space in CE-MRA [6,7].
The T1 relaxivity and in vivo half-life of a contrast agent
becomes even more critical in small animal imaging, where the
vessels are much smaller than in humans, resulting in longer scan
times and therefore increased propensity to extravasate into the
extravascular space. In recent work, this shortcoming was
highlighted in small animal imaging [8], where even under
optimized imaging conditions in a 7T scanner, it was not possible
to clearly image the intercostal and spinal vasculature in a rat with
conventional low molecular-weight Gd-chelates. Thus, agents that
remain intravascular and have greater T1-relaxivity per unit of
contrast agent are needed in order to amplify signal, improve
CNR, and enable vascular imaging with high vessel conspicuity.
The development of such agents is also being pursued in the
field of molecular MRI where the targets of interest, such as tumor
cells or cell-associated molecules, are present at micro- or nano-
molar concentrations. One approach to prepare such an agent is
to associate Gd-chelates with a nanoparticle. Several nanoparticle-
based platforms have been utilized to develop signal amplification
contrast agents [9,10,11]. One class of nanoparticles, liposomes,
has provided a unique platform for development of MR contrast
agents. Liposomes have been used for preparation of two separate
Gd-based constructs: core-encapsulated Gd (CE-Gd) liposomes
wherein the Gd-chelates are encapsulated in the interior core of
liposomes [12,13]; and surface-conjugated Gd (SC-Gd) liposomes
wherein the Gd-chelates are presented on the surface of liposomes
[14]. Compared to conventional Gd-chelates, liposomal-Gd agents
have long in vivo half life and have very low propensity to
extravasate except at regions of ‘leaky’ vasculature, such as tumor
blood vessels [15,16,17]. As a result, these agents provide an
extended imaging window for acquisition of high-resolution
images, thus enabling excellent small vessel depiction. This has
been demonstrated previously by imaging of sub-millimeter
vascular features of the CNS neurovasculature [8] and the
cardiovascular system [18] in small animals. From a molecular
MRI perspective, such nanoparticle agents are able to deliver a
high payload of Gd-chelates to the target site and therefore
amplify signal. In addition to molecular targeting, such nanopar-
ticle agents would also find applications in highlighting low levels
of vascular leak as observed in tumors [19].
We reasoned that the full capability of liposomes to amplify
signal has not been exploited and therefore tested whether
liposomes that both encapsulate and display gadolinium on their surface
would exhibit increased T1 relaxivity in vitro and whether this leads
to further signal enhancement in vivo. In this work, we therefore
investigated such ‘‘Dual-Gd’’ agents. In the rest of this paper, we
use the term CE-Gd (Core-Encapsulated) for nanoparticles that
encapsulated gadolinium within the core-interior, SC-Gd (Surface-
Conjugated) for those nanoparticles that have gadolinium
conjugated on the surface, and Dual-Gd for particles that have
both core-encapsulated and surface-conjugated gadolinium
(Figure 1).
Materials and Methods
1.1. Ethics Statement
All animals were handled in accordance with good animal
practice as defined by the relevant national and/or local animal
welfare bodies, and all animal work was approved by the
Institutional Animal Care and Use Committee (IACUC) of MD
Anderson Cancer Center. The MD Anderson Cancer Center
animal management program is accredited by the American
Association for the Accreditation of Laboratory Animal Care and
meets National Institute of Health standards as set forth in the
‘‘Guide for the Care and Use of Laboratory Animals’’ (DHHS
Publication No. (NIH) 85–23, Revised 1985). The institution also
accepts as mandatory the PHS ‘‘Policy on Humane Care and Use
of Laboratory Animals by Awardee Institutions’’ and ‘‘NIH
Principles for the Utilization and Care of Vertebrate Animals
Used in Testing, Research and Training’’.
1.2. Preparation of liposomal contrast agents
For preparation of CE-Gd liposomes, a lipid mixture consisting
of 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) (Gen-
zyme, MA), Cholesterol (Sigma-Aldrich, St Louis, MO) and
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(-
poly(ethylene glycol))-2000] (mPEG2000-DSPE) (Genzyme,
MA) in the molar ratio 55:40:5 was dissolved in ethanol.
Subsequently, the ethanol solution was mixed with a solution of
gadobenate dimeglumine (Multihance
H, Gd-BOPTA, 500 mM
Gd) to achieve a lipid concentration of 150 mM. The solution
was stirred for 90 minutes at 60uC and then sequentially
extruded on a Lipex Thermoline extruder (Northern Lipids,
Vancouver, British Columbia, Canada) with three passes
through a 400 nm Nuclepore membrane (Waterman, Newton,
MA), five passes through a 200 nm and ten passes through a
100 nm membrane. The resulting solution was diafiltered using
aM i c r o K r o s
H module (Spectrum Laboratories, CA) of 500 kDa
molecular weight cut-off to remove unencapsulated Gd-chelate
molecules.
For SC-Gd liposomes preparation, a lipid mixture consisting of
DPPC, Gd-DTPA bis(stearylamide) (Gd-DTPA-BSA) (IQsynth-
esis, St Louis, MO), Cholesterol and mPEG2000-DSPE in the
molar ratio 30:25:40:5 was dissolved in a chloroform: methanol
(1:1 v/v) mixture. The solvent mixture was evaporated to dryness
under vacuum and the lipid contents were hydrated with 150 mM
saline to achieve a lipid concentration of 40 mM. The solution was
stirred for 90 minutes at 60uC and then sequentially extruded with
five passes through a 400 nm Nuclepore membrane, seven passes
through a 200 nm Nuclepore membrane and ten passes through a
100 nm Nuclepore membrane.
For preparation of Dual-Gd liposomes, a lipid mixture
consisting of DPPC, Gd-DTPA-BSA, Cholesterol and
mPEG2000-DSPE in the molar ratio 30:25:40:5 was dissolved
in a chloroform: methanol (1:1 v/v) mixture. The solvent
mixture was evaporated to dryness under vacuum and the lipid
Figure 1. Schematic of various liposomal-Gd agents. Core-
encapsulated gadolinium (CE-Gd) liposomes contain conventional low
molecular-weight Gd-chelates in the core interior of the liposomes,
surface-conjugate gadolinium (SC-Gd) liposomes contain Gd-chelates
conjugated on the internal and external surface of the liposome bilayer,
Dual-Gd liposomes contain both core-encapsulated and surface-
conjugated Gd-chelates. The stars represent Gd-chelates.
doi:10.1371/journal.pone.0007628.g001
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mine (Multihance
H, Gd-BOPTA, 500 mM Gd) to achieve a lipid
concentration of 40 mM. The solution was stirred for 90 minutes
at 60uC and then sequentially extruded with five passes through a
400 nm Nuclepore membrane, seven passes through a 200 nm
N u c l e p o r em e m b r a n ea n dt e np a s s e st h r o u g ha1 0 0 n m
N u c l e p o r em e m b r a n e .T h er e s u l t i n gs o l u t i o nw a sd i a f i l t e r e d
u s i n gaM i c r o K r o s
H module (Spectrum Laboratories, CA) of
500 kDa molecular weight cut-off to remove unencapsulated Gd-
chelate molecules. To demonstrate reproducibility in the
synthesis process, two different batches of each liposomal agent
were prepared and characterized as described below.
1.3. Characterization of liposomal agents
1.3.1. Particle size and composition. The size distribution
of liposomes in the final formulation was determined by dynamic
light scattering (DLS) using a ZetaPlus Analyzer (Brookhaven
Instruments, Chapel House, UK) at 25uC. The gadolinium and
phosphorus content of liposomal formulations were quantified
using inductively coupled plasma optical emission spectroscopy
(ICPOES; Model Optima 4300D, Perkin Elmer, Norwalk, CT)
operating at a wavelength of 336.223 nm for gadolinium and
213.617 nm for phosphorus. The number of gadolinium atoms
per liposome was calculated based on the Gd:P ratio, mean
liposome diameter, and the respective phospholipid molar
composition for each formulation.
1.3.2. Measurement of Gd-based molar T1
relaxivity. Samples with gadolinium concentrations ranging
between 0.25 mM–2 mM (5 samples) were prepared by diluting
the liposomal solutions in bovine plasma. T1 relaxation
measurements were performed on a 60 MHz Minispec MQ
series benchtop relaxometer (Bruker Optics) at 37uC. The
longitudinal relaxation rates (R1) of the diluted samples were
obtained using an inversion recovery method. A plot of R1 versus
gadolinium concentration yielded a straight line with the slope
defined as the T1 relaxivity (r1). To demonstrate reproducibility in
T1 relaxation times, measurements were repeated after one week
by preparing fresh dilutions in bovine plasma.
1.3.3. Measurement of T1 relaxation rates for different
lipid dose. The T1 relaxation rates (R1) of three liposomal
contrast agents were also compared on a particle basis. Dilutions
were done on a lipid-dose basis i.e., amount of lipid administered
(mg) per body weight (kg). Diluted samples were prepared in
bovine plasma to achieve lipid concentrations ranging between
40–400 mg lipid/kg of human body weight. The chosen
concentration range represents contrast agent doses that are
likely to enable sufficient SNR for in vivo imaging. To demonstrate
stability and reproducibility in T1 relaxation times, measurements
were repeated after one week by preparing fresh dilutions in
bovine plasma.
1.3.4. Calculation of nanoparticle-based T1 relax-
ivity. To calculate T1 relaxivity on a nanoparticle-basis, the
above lipid-dose was converted into nanoparticle concentration. An
average lipid molecular weight was determined using the molecular
weight and molefraction of eachlipid used in liposome preparation.
The nanoparticle concentration was then determined using the
number of lipids per liposome and average lipid molecular weight.
A plot of R1 versus liposome concentration yielded a straight line
with the slope defined as the nanoparticle-based T1 relaxivity (r1).
1.4. In vivo Imaging
1.4.1. Animal preparation. Six nude mice were used for the
studies. For in vivo comparison of different liposomal formulations,
the agents were intravenously administered via the tail vein at a
lipid dose of 200 mg/kg. The corresponding gadolinium doses
were 0.07, 0.08 and 0.15 mmoles/kg for CE-Gd, SC-Gd and
Dual-Gd, respectively. The same animals were used for all three
agents, in a randomized order. On day 1, each mouse received a
randomly selected agent (1: CE-Gd, 2: SC-Gd, 3: Dual-Gd). After
imaging, the animals were returned to their cages for a minimum
of 3 days. At the second imaging session, mice received the next
agent in the list, i.e., mice that had received CE-Gd earlier then
received SC-Gd, mice that had received SC-Gd earlier then
received Dual-Gd and mice that had received Dual-Gd earlier
then received CE-Gd. The animals then progressed to the next
contrast agent in the third imaging session. Inhalation of 2%
isofluorane was used for anesthesia.
1.4.2. MR Imaging Protocol. All MR studies were
performed on a 4.7T scanner (Bruker BioSpec, 47/40 USR,
Bruker Biospin, Billerica, MA) using a 60-mm gradient insert and a
volume resonator with a 35 mm inner diameter. Animals were
anesthesized and placed head first and prone on a positioning sled.
Orthogonal 3-plane scout scans were initially acquired for animal
positioning. Pre-contrast and post-contrast MRA images were
acquired using a heavily T1-weighted 3D fast spoiled gradient echo
sequence (FSPGR). Scans were acquired with the following imaging
parameters:repetitiontime (TR)=5.0 ms;echotime (TE)=2.1 ms;
flip angle (FA)=30u; field of view (FOV)=30630630 mm
3; Image
matrix=12861286128; number of signal averages=5. This
resulted in an isotropic voxel size of 320 mm. The total scan time
was under seven minutes. Maximum intensity projection (MIP)
images were performed and analyzed.
1.5. Image Analysis
Signal to noise ratios (SNRs) and contrast-to-noise ratios (CNRs)
were calculated for regions of interest in the jugular veins and
muscle. The SNR was calculated as SIv=SD where, SIv is the mean
signal intensity within the blood vessel and SD is the standard
deviation of the signal intensity within the background (air). The
CNR was defined as SIv{SIm ðÞ =SD where, SIm is the mean signal
intensity in the muscle region. Pre-contrast SNRs were subtracted
from post-contrast SNRs to minimize differences in baseline
signals from animal to animal. Similarly, pre-contrast CNRs were
subtracted from post-contrast CNRs. SNRs and CNRs calcula-
tions were performed for each animal and then average values
were reported for the group (n=6).
1.6. Statistical Analysis
For comparing groups, two-tailed t-tests were performed using
spreadsheet software (Microsoft Office Excel 2003, Microsoft,
Seatle, WA). A P-value of less than 0.05 was considered statistically
significant.
Results
The three liposomal-gadolinium formulations demonstrated
good reproducibility in the fabrication process (Table 1). Size
analysis of liposomes indicated particles of approximately 100 nm
in diameter. The low polydispersity index for various formulations
indicated narrow size distributions. More than 95% of liposomes
in all the three formulations were below 150 nm. No significant
changes in size distribution were observed over a one month
period (data not shown). The Dual-Gd liposomes had the highest
gadolinium to phospholipid (Gd:P) ratio. The calculated number
of Gd per liposome were also highest for the Dual-Gd formulation.
This was due to the presence of two gadolinium pools in Dual-Gd
liposomes – the core-encapsulated pool and the surface-conjugated
pool. Since the lipid composition and molarity for SC-Gd
Nanoparticle Agent for MRI
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similar surface-Gd per liposome for both agents. The higher Gd
per liposome observed for Dual-Gd compared to the sum total of
CE-Gd and SC-Gd liposomes is therefore most likely a result of
increased encapsulated Gd fraction compared to the CE-Gd
liposomes. This is most likely due to the larger liposome size
obtained for Dual-Gd liposomes compared to the CE-Gd
liposomes.
The Gd-based molar T1 relaxivities (r1) of the three liposomal
formulations were also compared. SC-Gd liposomes demonstrated
the highest r1 whereas CE-Gd liposomes had the lowest (Figure 2).
The r1 of Dual-Gd was significantly lower than that of SC-Gd
(p,0.05). The higher r1 observed for SC-Gd is a result of more
liposomal particles present per unit concentration of Gd.
Consequently, more Gd atoms are exposed to the bulk water
molecules which eventually results in an enhanced T1 relaxation
effect. No significant changes in the r1 were observed over a one
week period (data not shown).
To compare the relaxation properties of liposomal formulations
on a particle basis, in vitro T1 relaxation rates (R1) were measured
for diluted samples prepared in bovine plasma. The dilutions were
performed on a lipid-dose basis i.e., amount of lipid administered
(mg) per unit of body weight (kg). The Dual-Gd and SC-Gd
liposomes had at least two-fold higher relaxation rates compared
to CE-Gd liposomes at all lipid doses (p,0.05, Figure 3). The
Dual-Gd liposomes demonstrated the highest R1 on a particle-
basis among the three formulations (p,0.05 Dual-Gd vs SC-Gd,
Figure 2). The higher R1 for Dual-Gd liposomes is a combined
effect of surface-conjugated and core-encapsulated gadolinium
which causes more protons to relax compared to either SC-Gd or
CE-Gd liposomes. This is also evident in the T1 relaxivities
calculated on a nanoparticle-basis (Figure 4). Dual-Gd liposomes
demonstrated the highest nanoparticle-based T1 relaxivity. The
nanoparticle-based T1 relaxivities were more than three orders of
magnitude (2000–8000) higher than conventional low molecular-
weight contrast agents such as Gd-DTPA. The high T1 relaxivities
is a result of their ability to carry several thousands of Gd-chelates
per nanoparticle.
To compare different liposomal formulations in vivo, the agents
were administered at identical lipid dose i.e., resulting in
equivalent liposome concentration in the blood. For comparison
purposes, all maximum intensity projection (MIP) images were
processed to identical brightness/contrast levels. All three agents
demonstrated visualization of large vessels (Figure 5). However,
Dual-Gd and SC-Gd liposomes better demonstrated small vessel
features as seen in the coronal MIP images. Increased signal and
relatively lower background were noted in the Dual-Gd images, in
addition, smaller vessels became even more conspicuous. This is
reflected in the SNR and CNR values (Figure 6), which show that
Table 1. Characterization of liposomal-Gd formulations.
Agent Mean Diameter (nm) Polydispersity Index Cumulative particle size distribution Gd:P ratio Gd per liposome
% ,200 nm % ,150 nm % ,100 nm
CE-Gd Batch-1 9962 0.054 100 $97 $75 0.398 34783
Batch-2 9462 0.022 100 $99 $80 0.375 29420
SC-Gd Batch-1 11063 0.012 100 $95 $60 0.784 49743
Batch-2 10963 0.035 100 $96 $60 0.782 48685
Dual-Gd Batch-1 11464 0.042 100 $93 $53 1.648 112590
Batch-2 10763 0.054 100 $97 $62 1.560 93462
doi:10.1371/journal.pone.0007628.t001
Figure 2. T1 relaxivity of liposomal-Gd formulations on a per
Gadolinium basis. Measurements were performed at 1.5 Tesla MR
field strength in bovine plasma at 37uC. Each value is significantly
different (p,0.05).
doi:10.1371/journal.pone.0007628.g002
Figure 3. T1 relaxation rates (R1) of liposomal-Gd formulations
for different lipid doses. Measurements were performed at 1.5 Tesla
MR field strength in bovine plasma at 37uC. For each lipid dose, the R1
values were significantly different for each of the liposomal-Gd agent
(* corresponds to p,0.05).
doi:10.1371/journal.pone.0007628.g003
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then CE-Gd. The differences in SNR and CNR values for all three
agents were statistically significant (p,0.05). The better demon-
stration of vascular features by Dual-Gd, relative to the other two
agents, is a result of higher Gd delivered (both surface-conjugated
and core-encapsulated) per nanoparticle.
Discussion
The need to increase MRI image contrast, both as measured by
signal-to-noise (overall brightness) and contrast-to-noise (feature
conspicuity) ratio is a constant thrust in the field of contrast agent
development. Nanoparticle-based contrast agents are particularly
interesting because they can be used to amplify signal by delivering
more contrast agent molecules to an area of interest; therefore,
improving both overall signal and feature conspicuity. For vascular
imaging, SNR and CNR may be improved by nanoparticles
contrast agents with (1) decreased propensity for indiscriminate
extravasation, thus, reducing vessel blurring; and, (2) long
intravascular circulation time, thus, reducing the need for bolus
tracking. This permits acquisition of high-resolution scans with
several image signal averages. This should aid small feature
analysis that is critical in imaging of small animals and in clinical
decision making.
In addition, the capability to deliver a large payload of Gd is
also quite attractive for molecular imaging. Molecular targeting of
individual contrast molecules results in a typical 1:1 target-to-
readout ratio. Since molecular targets, such as receptors present in
the vasculature, are often present in micro- or nano-molar
concentrations, readouts will also typically be in this concentration
range. This has made molecular imaging the domain primarily of
nuclear imaging methods, which have high sensitivity to detect
such low concentration ranges. With nanoparticles, the ratio of
contrast agent to target can be dramatically increased so that
thousands of imaging agents are localized per particle bound to the
target. Thus, measuring the relaxivity on a particle-molar basis is a
good way of estimating the signal achievable for nanoparticle-
based contrast agents [20].
Several macromolecular and nanoparticle-based platforms have
been investigated for the development of blood pool and molecular
MRI contrast agents. MS-325, an albumin-binding Gd-chelate was
recently approved for use as a blood pool MR contrast agent in
USA. While the agent is known to demonstrate persistent blood
pool contrast, the mechanism of action is based on transient
interactions with human serum albumin (HSA) and therefore is
likely to exhibit variability in signal enhancement due to on-off
binding [21]. In the nanoparticle-domain, three major platforms
have been investigated. Lipid-based paramagnetic perfluorocarbon
(PFC) nanoparticles have been used as molecular MRI contrast
Figure 4. T1 relaxivity of liposomal-Gd formulations on a per
nanoparticle basis.
doi:10.1371/journal.pone.0007628.g004
Figure 5. In vivo comparison of liposomal-Gd contrast agents. Coronal maximum intensity projection (MIP) images of the head and thorax in
mice acquired pre-contrast, post CE-Gd liposomes, post SC-Gd liposomes and post Dual-Gd liposomes. The contrast agents were administered
intravenously at a lipid dose of 200 mg/kg. Please note the increased signal in the vessels compared to background and the high vessel conspicuity
for smaller vessels (arrows in the Dual-Gd image). All images were acquired in different animals using the 3D-FSPGR sequence. The MIP images are
presented at identical gray-scale levels.
doi:10.1371/journal.pone.0007628.g005
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nanoparticles is around 250 nm, thus enabling higher surface
incorporation of Gd per nanoparticle and therefore higher
nanoparticle-based relaxivity compared to smaller Dual-Gd agents
described here. Dendrimers-based gadolinium nanoparticles have
also been extensively investigated for use as blood pool and
molecular MRI contrast agents [11]. The use of dendrimer as a
platform enables synthesis of a broad range of particle sizes,
however, the payload of Gd that can be delivered is limited by the
number of conjugation sites available on the dendrimer. Liposomes
have also been extensively investigated for use as contrast agents. A
particular problem with CE-Gd liposomes has been the inability to
generate a large amount of T1 relaxivity due to limited proton
exchange between the interior and exterior of liposomes because of
the liposomal bilayer [13]. The presentation of Gd-chelates on the
surface of nanoparticles in SC-Gd liposomes have resulted in equal
or higher T1 relaxivities compared to conventional contrast agents.
However, the number of sites for Gd-chelate conjugation on the
liposome are limited to about 25% of the number of surface lipid
molecules because larger percentages tend to destabilize the
membrane [14]. Although this limits the total enhancement that
is achievable using surface Gd, alternate liposome-based structures
that exhibit higher relaxivity are feasible and could further improve
image quality. Liposomes containing Gd-chelates complexed to
very short polymeric chains of ethylene glycol (PEG) have also been
investigated [22]. The complexation of Gd on the flexible polymers
resulted in higher T1 relaxivity on a Gd-basis. However, the
relatively short PEG chains (2 monomer units) used in their
preparation would result in faster clearance of their agent.
The T1 relaxivities of free Gd-chelates are on the order of 3–5
(mM.sec)
21; whereas, Dual-Gd provides a nanoparticle-based T1
relaxivity of 35000 (mM.sec)
21, which is approximately 10
4 times
higher than that of free Gd-chelate. PFC-based nanoparticles have
been reported to have higher nanoparticle-based relaxivities than
Dual-Gd liposomal agents [20]. The high relaxivities of PFC
nanoparticles is due to their broad and large particle size
distribution and the fact that all Gd-chelates, present in the lipid
monolayer, are exposed to the bulk water. The differences in mean
particle size diameter and size distribution between Dual-Gd
liposomes and PFC-based nanoparticles therefore precludes direct
comparison of such agents on a nanoparticle-basis. However, the
development of such nanoparticles with high signal amplification
begins to bring molecular imaging into the realm of MRI. This in
turn has huge potential advantages since MRI, unlike nuclear
imaging techniques, can demonstrate anatomy along with the
molecular target, with enormously high spatial resolution. Thus,
Dual-Gd is a key step on this path.
Another key parameter that characterizes a nanoparticle-based
contrast agent is the number of particles injected in order to
generate sufficient image contrast. This has implications ranging
from the potential for infusion-related reactions to the ultimate
clearance route and toxicity. Infusion related reactions, which can
cause complement-activation related pseudoallergies (CARPA),
are sensitive to physicochemical properties of nanoparticles [23].
Clearance of nanoparticles is usually via the reticulo-endothelial
system (RES), and a high particle load could lead to RES overload,
thus compromising the body’s ability to clear other particulate
species. A lower dose of a contrast agent with high relaxivity can
be injected to achieve the same signal enhancement as a larger
quantity of an agent with lower relaxivity. Thus, the relaxivity on a
molar basis of nanoparticles is critically important to avoid toxicity
and other complications.
Dual-Gd, being based on the well known PEGylated (Stealth)
liposome platform, has several advantages. First, it is a versatile
platform, as demonstrated by the easy preparation of 3 different
variants in this work (CE, SC and Dual). Second, there is much
known about the safety and disposition of such liposomes in the
body; indeed, there are therapeutic products already in clinical use
that are based on this platform [24]. However, the safety and
disposition of Gd-based liposomal agents needs to be further
investigated. The long circulating property of Stealth liposomes,
coupled with their controlled extravasation in regions of vascular
compromise, make this class of agents quite attractive for
visualizing vascular lesions. Moreover, there is much known about
the molecular targeting of Stealth liposomes [25–27]. To capitalize
on these advantages, improving the T1 relaxivity per particle is
critical. The orders of magnitude improvement in relaxivity
achieved per nanoparticle with Dual-Gd compared to conven-
tional Gd-chelate agents should enable improved vascular imaging
and paves the way for molecularly-targeted MR imaging.
Figure 6. In vivo comparison of signal to noise ratios (SNR) (Fig. A) and contrast to noise ratios (CNR) (Fig. B) for different liposomal-
Gd agents. Each agent was administered in mice at a lipid dose of 200 mg/kg. There was significant difference within the SNRs and CNRs of various
contrast agents (p,0.05).
doi:10.1371/journal.pone.0007628.g006
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We have demonstrated a new nanoparticle-based Gd agent for
T1-weighted MR imaging. The new agent, named Dual-Gd
liposomal agent, combines features of two previously described
agents, CE-Gd (core-encapsulated Gd liposome) and SC-Gd
(surface-conjugated Gd liposome) to create a new entity that is
capable of delivering a higher concentration of Gd, thus greater
signal enhancement per particle. Upon in vivo imaging, the Dual-
Gd resulted in both improved SNR and CNR. Among other
applications, the agent should find use in vascular imaging,
particularly for evaluation of small features that can be critical for
clinical decision making and for imaging of small animals; as well
as, in molecular imaging, where the number of imaging agents per
particle bound to the target is critical for creating sufficient signal
for target identification.
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